March 4, 2013 - Atlanta, GA. The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection. Continue Reading...
Do you get our newsletter?
Sign up for our monthly Newsletter and get the latest info in you in box.
Learn why clinical trials are done, what types there are, how to decide whether to participate, and why it's important for women to be involved.
The report from the 2007 WRI meeting updates many of the ongoing efforts of the WRI which have been developed since WRI's inception in 2003.